IP Library Granted Patent US 9,382,515
Granted Patent B2
US 9,382,515 · App. 12/595,041 · Granted Jul 5, 2016

Reprogramming of somatic cells

Inventors: Rudolf Jaenisch (Brookline, MA); Yaqub Hanna (Boston, MA); Marius Wernig (Woodside, CA); Christopher J. Lengner (Wellesley, MA); Alexander Meissner (Cambridge, MA); Oliver Tobias Brambrink (Cambridge, MA); G. Grant Welstead (Cambridge, MA); Ruth Foreman (Somerville, MA)
Assignee: Whitehead Institute for Biomedical Research
C12N5/0696C07K14/4702A01K67/0273A01K67/0275A01K2217/05A01K2227/105C12N15/8509C12N15/8775C12N2501/602C12N2501/603C12N2501/604C12N2501/605C12N2501/606C12N2506/11C12N2506/13C12N2800/30C12N2830/003C12N2830/006G01N33/5023G01N2333/91011
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,382,515
App. No.
12/595,041
Granted
Jul 5, 2016
Kind
B2
Abstract

The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.

Claims (11)

1. A purified preparation of isolated pluripotent mammalian cells, wherein the cells

(a) express endogenous Oct4 and Nanog;

(b) differentiate into tissues having the characteristics of endoderm, mesoderm, and ectoderm when injected into SCID mice;

(c) do not express a nucleic acid encoding a selectable marker operably linked to an endogenous pluripotency gene; and

(d) are reprogrammed mammalian somatic cells that comprise exogenously introduced polynucleotides encoding Oct4, Sox2, and Klf4, but not c-Myc.

2. The purified preparation of cells of claim 1 , wherein at least about 50% of the cells are resistant to DNA methylation.

3. The purified preparation of cells of claim 1 , wherein the cells survive and DNA methyltransferase I expression in the cells is reduced by at least 50%.

4. The purified preparation of cells of claim 1 , wherein the genome of said cells is not genetically modified.

5. The purified preparation of cells of claim 1 , wherein said cells comprise at least one genetic modification of the genome of said cells.

6. The purified preparation of cells of claim 1 , wherein the cells are genetically matched to a donor of said somatic cells or a donor of a precursor cell of said somatic cells, wherein said donor is an individual in need of cell therapy.

7. The purified preparation of cells of claim 1 , wherein the cells do not express an exogenously introduced pluripotency gene.

Assignments (2)
CONFIRMATORY LICENSE Recorded Oct 25, 2018
From: WHITEHEAD INSTITUTE FOR BIOMEDICAL RES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047723/0674 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 26, 2011
From: JAENISCH, RUDOLF; HANNA, YAQUB; WERNIG, MARIUS; LENGNER, CHRISTOPHER J.; MEISSNER, ALEXANDER; BRAMBRINK, OLIVER TOBIAS; WELSTEAD, G. GRANT; FOREMAN, RUTH
To: WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH
Reel/Frame 026349/0593 →
Continuity (4)
Provisional Application 61036065 · Mar 12, 2008
Provisional Application 60959341 · Jul 12, 2007
Provisional Application 60922121 · Apr 7, 2007
Related Publication 20110076678A1 · Mar 31, 2011